KR102199537B1 - Composition for preventing and treating of obesity or metabolic disease comprising extract from Jeju Udo peanut Sprouts - Google Patents

Abstract

The present invention relates to a composition for the prevention and treatment of obesity or metabolic diseases comprising the Udo peanut sprout extract, wherein the Udo peanut sprout extract of the present invention inhibits fat differentiation of adipocytes, inhibits lipid accumulation in mature adipocytes, and , By showing the effect of increasing fatty acid oxidation and increasing mitochondrial energy activity through AMPK activation, it can be usefully used in the prevention, improvement or treatment of metabolic diseases such as obesity.

Description

Composition for preventing and treating obesity or metabolic disease comprising extract from Jeju Udo peanut Sprouts}

The present invention relates to a composition for the prevention and treatment of obesity or metabolic diseases comprising a peanut sprout extract.

In modern Korea, due to social and economic development, dietary life is gradually becoming westernized, and the obese population is gradually increasing due to excessive intake of nutrients and decrease in physical activity due to changes in the living environment. Obesity refers to a phenomenon in which fat is excessively accumulated in the body, not simply an increase in body weight due to an imbalance between energy intake and consumption. In particular, obesity was found to be the cause of various metabolic diseases such as diabetes, hyperlipidemia, cardiovascular disease and arteriosclerosis, as well as lowering the quality of life due to an increase in mental stress and depression due to external changes.

Fat stored in fat cells is used as an important energy source in the body. However, as obesity progresses, not only the number of adipocytes increases, but also the synthesis of large amounts of triglycerides due to excessive differentiation of adipocytes is accompanied by morphological changes including an increase in the size of adipocytes and changes in the expression of several genes. The increase in the size of adipocytes is induced by synthesizing and storing excess energy in the form of triglycerides. On the other hand, according to the storage of fat, the size of adipocytes can increase up to 20 times in diameter, and as a result, cell volume is known to increase up to several thousand times. In general, the size of adipocytes can be adjusted by dietary control, but the process of differentiation of new pro-adipocytes into adipocytes is not effective through dietary control. It is important to adjust. Adipocyte differentiation is promoted by stimulation of insulin, insulin like growth factor-1 (I) and growth hormone, and in this process, the CCAAT enhancer-binding protein (C/EBP) family, An increase in transcription factors such as peroxisome proliferator-activated receptor (PPAR) gamma is observed. These transcription factors, along with adipocyte regulators, promote the differentiation of adipocytes, and the expression levels of enzymes such as aP2, a fatty acid binding protein, and fatty acid synthase, increase. Meanwhile, it has been reported that excessive accumulation of triglycerides is involved in the progression of fatty liver [J Clin Invest, 98, 1575 ~1584 (1996)].

In general, fat is divided into white fat, which stores excess energy, and brown fat with a number of mitochondria, and excess energy intake is defined as white adipose tissue expansion, and existing obesity control studies focus on white fat-related mechanisms. Brown fat, which has a lot of mitochondria, was not known to exist in adults. According to recent research results, it has been reported that brown adipocytes may exist in adults, and it is known that brown fatization of white adipocytes is possible by exposure to a specific environment (eg, exposure from cold or exercise). Characteristic in the browning of white fat are the increased expression of uncoupling protein1 (UCP1) present in the inner membrane of the mitochondria, irisin in the muscle, and the gene secreted by FGF-21 in the liver is expressed and binds to some cells. It has been reported that the presence of cells and their ratio increase, as well as the number of mitochondria, as well as the number of mtDNA, a characteristic genome within the mitochondria. These characteristics accompany the change in the regulation of mitochondrial metabolism, which is the key to energy metabolism, and increase energy consumption, so it is essential to investigate the role of mitochondria for regulating energy metabolism in adipocytes.

Currently, treatments for obesity include Orlistat, which inhibits the digestion and absorption of fat, fluoxetine, which suppresses appetite, fendimethrazine, and ephedrine, a metabolic accelerator. However, the conventional treatments as described above have side effects such as heart disease, respiratory disease, and nervous system disease, as well as low persistence of their efficacy, and thus further improved obesity treatment is required.

Accordingly, the present inventors completed the present invention by confirming that the Udo peanut sprout extract can inhibit fat accumulation and production while conducting research on the physiological activity of the peanut sprout extract.

Korean Patent Registration No. 10-1910099

An object of the present invention is to provide a pharmaceutical composition for preventing or treating metabolic diseases.

Another object of the present invention is to provide a health food composition for preventing or improving metabolic diseases.

Another object of the present invention is to provide a health functional food composition for preventing or improving metabolic diseases.

To achieve the above object,

The present invention provides a pharmaceutical composition for the prevention or treatment of metabolic diseases comprising the Udo peanut sprout extract.

In addition, the present invention provides a health food composition for preventing or improving metabolic diseases, including the Udo peanut sprout extract.

Furthermore, the present invention provides a health functional food composition for preventing or improving metabolic diseases, including the Udo peanut sprout extract.

Udo peanut sprout extract of the present invention inhibits fat differentiation of adipocytes, inhibits lipid accumulation in mature adipocytes, increases fatty acid oxidation through AMPK activation, and increases mitochondrial energy activity, thereby preventing metabolic diseases such as obesity. It can be usefully used for prevention, improvement or treatment.

1 is raw data of Udo peanut sprout extract.
2 is raw data of peanut sprout extracts from other regions.
Figure 3 shows the effect of the Udo peanut sprout extract on cell viability.
Figure 4 shows the effect of suppressing adipogenesis in 3T3-L1 adipocytes of Udo peanut sprout extract.
5 shows the effect of suppressing adipogenesis in 3T3-L1 adipocytes of Udo peanut sprout extract through gene expression.
6 shows the effect of suppressing adipogenesis in 3T3-L1 adipocytes of Udo peanut sprout extract through protein expression.
7 shows the effect of suppressing adipogenesis in C3H10T1/2 adipocytes of Udo peanut sprout extract.
Figure 8 shows the effect of suppressing fat production in Primary adipocyte of Udo peanut sprout extract.
Figure 9 shows the effect of the Udo peanut sprout extract on fatty acid oxidation.
Figure 10 shows the effect on the brown localization of Udo peanut sprout extract.
Figure 11 shows the effect of the Udo peanut sprout extract on mitochondrial energy activity.

Hereinafter, the present invention will be described in detail.

Pharmaceutical composition for preventing or treating metabolic diseases

The present invention relates to a composition for the prevention or treatment of metabolic diseases comprising a peanut sprout extract of Udo.

The term "extract" as used in the present invention refers to a preparation obtained by obtaining an extraction target as an appropriate leach solution and evaporating the leachate to concentrate, but is not limited thereto, but is not limited to an extract obtained by an extraction treatment, a diluted solution of the extract, or It may be a dried product obtained by drying a concentrate or an extract, and a crude or purified product thereof. The Udo peanut sprout extract can be prepared using a general extraction method, separation and purification method known in the art. As the extraction method, although not limited thereto, a method such as hot water extraction, hot water extraction, cold needle extraction, reflux cooling extraction, or ultrasonic extraction may be used. In the present invention, the Udo peanut sprout extract was obtained by extracting a peanut sprout obtained by germinating peanut seeds from Udo, Jeju, and extracted with hot water under pressure to obtain a Udo peanut sprout extract. According to an embodiment of the present invention, the Udo peanut sprout extract of the present invention contains 6 times the amount of resveratol than the peanut sprout extract of other regions (see Table 4).

In the pharmaceutical composition according to the present invention, the metabolic disease may be any one or more selected from the group consisting of obesity, diabetes, hyperlipidemia, hypercholesterolosis, arteriosclerosis and fatty liver, preferably obesity, hyperlipidemia, hypercholesterolosis. And it may be any one or more selected from the group consisting of fatty liver, more preferably may be obesity.

In one embodiment of the present invention, the Udo peanut sprout extract of the present invention inhibits fat differentiation of adipocytes, inhibits lipid accumulation in mature adipocytes, increases fatty acid oxidation through AMPK activation, and increases mitochondrial energy activity. By showing, it was confirmed that metabolic diseases such as obesity can be prevented, improved, or treated (see Experimental Examples 4 to 8).

Udo peanut sprout extract of the present invention can be administered in various oral and parenteral formulations at the time of clinical administration, and when formulated, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. It is manufactured using.

Solid preparations for oral administration include tablets, patients, powders, granules, capsules, troches, and the like, and these solid preparations include at least one excipient, such as starch, carbonic acid, in one or more of the Udo peanut sprout extract of the present invention. It is prepared by mixing calcium, sucrose, lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, or syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, are included in addition to water and liquid paraffin, which are commonly used simple diluents. I can.

Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories, and the like. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used as the non-aqueous solvent and the suspension. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, and the like may be used.

The effective dosage for the human body of the Udo peanut sprout extract of the present invention may vary depending on the age, weight, sex, dosage form, health condition and degree of disease of the patient, and is generally about 0.01-1000 mg/kg/day, Preferably, it may be 0.1-500 mg/kg/, and may be dividedly administered once a day or several times a day at predetermined time intervals according to the judgment of a doctor or pharmacist.

The pharmaceutical composition of the present invention may further contain a known therapeutic agent for metabolic diseases in addition to the Udo peanut sprout extract as an active ingredient, and may be used in combination with other known treatments for the treatment of these diseases.

Health functional food and health food composition for preventing or improving metabolic diseases

The present invention relates to a health functional food or health food composition for the prevention or improvement of metabolic diseases comprising the Udo peanut sprout extract.

When using the Udo peanut sprout extract of the present invention as a health functional food and a health food composition, there is no particular limitation on the type of food. Examples of foods to which the Udo peanut sprout extract of the present invention can be added include drinks, meat, sausages, bread, biscuits, rice cakes, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, and dairy including ice cream. There are products, various soups, beverages, alcoholic beverages and vitamin complexes, dairy products and dairy products, and include all health functional foods and health food compositions in the usual sense.

The health functional food and health food composition containing the Udo peanut sprout extract according to the present invention may be added as it is to food or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the Udo peanut sprout extract can be appropriately determined according to the purpose of use (for prevention or improvement). In general, the amount of the composition in the health functional food and health food composition may be added in 0.1 to 90 parts by weight of the total food weight. However, in the case of long-term intake for the purpose of maintaining health or for the purpose of health control, the amount may be less than the above range, and there is no problem in terms of safety, so the Udo peanut sprout extract may be used in an amount above the above range. .

The health functional food and health food composition of the present invention is not particularly limited to other ingredients other than containing the peanut sprout extract of the present invention as an essential ingredient in the indicated ratio, and various flavoring agents or natural carbohydrates, etc. are added as in ordinary beverages. It can be contained as an ingredient. Examples of the natural carbohydrates described above include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 of the health functional food and health food composition of the present invention.

In addition to the above, the health functional food and health food composition containing the Udo peanut sprout extract of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and heavy weight agents (cheese, Chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like. In addition, the health functional food and health food composition of the present invention may contain flesh for the manufacture of natural fruit juice and fruit juice beverage and vegetable beverage.

These components may be used independently or in combination. Although the proportion of these additives is not so important, it is generally selected from 0.1 to about 20 parts by weight per 100 parts by weight of the health functional food and health food composition containing the Udo peanut sprout extract of the present invention.

Hereinafter, the present invention will be described in more detail by the following examples. However, the following examples are merely illustrative of the present invention, and the contents of the present invention are not limited by the following examples.

<Example 1> Udo peanut sprout extract (Peanut Sprouts Extract, PS) preparation

Udo peanut sprouts used in the present invention were supplied and used in May-June 2018 from “Wooyoung E&T Co., Ltd.”, and peanut sprouts aged 9 days after germination were used. Udo peanut sprout extract manufacturing method was conducted based on 2015 such as Miran et al. Peanut sprouts were dried in a hot air dryer at 60° C. for 24 hours and freeze-dried. Dried peanut sprouts are crushed finely, 15 times of distilled water is added to pressurized hot water extraction for 1 hour, filtered, placed in a zipper bag, lyophilized to obtain an extract, dissolved in DMSO and filtered (0.22um) for use in the experiment. I did. A sample of 100 mg/ml was prepared and used in subsequent experiments.

<Preparation Example 1> Cell culture

The 3T3-L1 cell line was pre-sale and used by Korean Cell Line Bank (Seoul, Korea). In Dubbecco's modified Eagle's medium (DMEM, Gibco, USA) containing 10% bovine calf serum (BCS, Gibco, USA) and 1% Pennicillin-sterptomycin (P/S, Gibco, USA) at 37℃, 5% O ₂ Incubated under conditions. 3T3-L1 adipocytes were replaced with fresh medium every 2 days, and when the cells reached 70-80% density, they were subcultured with 0.25% trypsin-EDTA. To induce differentiation into adipocytes, the cells were dispensed in a 96 well or 6 well plate at a concentration of 0.5-1x10 ⁶ cells/well, cultured until the cells became confluent, and then replaced with fresh medium for an additional 48 hours. DMEM containing 10% FBS, 1% P/S, 250uM Dexamethasone (Sigma, USA), 3-isobutyl-1-methylaxanthin (IBMX, Sigma, USA) and 10ug/ml insulin, which are differentiation inducing media in confluent state. Differentiation was induced for 2 days by exchange with the medium. Udo peanut sprout extract was treated with a differentiation inducing solution at a concentration of 5-200ug/ml.

C3H10T1/2 cells and primary adipocytes were cultured in DMEM medium containing 10% FBS and 1% P/S under the same conditions. Differentiation of C3H10T1/2 cells was differentiated in 1mM dexamethasone, 0.5 mM isobutyl-methylxantine, 0.01 mg/ml insulin, and 10% FBS in DMEM, and then insulin (0.01 mg/ml) and 1uM of rosiglitazone were used as adipocyte maintenance culture. Added.

To prepare the culture of rodent adipocytes, ear mesenchymal stem cells (EMSCs) were obtained from the ears of Balb/c mice. Briefly, EMSC was isolated from mature mice (n=3-4) by collagenase digestion (2mg/ml). The culture of EMSC was adipogenic differentiation according to the standard adipocyte differentiation protocol (Gawronska-Kozak B et al. 2014).

<Experimental Example 1> Measurement of total phenol and total flavonoid content

The total phenol content was measured by the Folin-Denis method (Kokkotbyul Kim et al., 2006). 50ul of a sample and 1M Folin-Ciocalteu's phenol reagent (FMD Millipore Corporation) were mixed and reacted at room temperature for 5 minutes. After mixing 100 μl of 4% Na ₂ CO ₃ to this solution, the solution was prevented for 60 minutes, and the absorbance was measured at 725 nm, and compared to the calibration curve using gallic acid (Sigma, USA), it was expressed as mg gallic acid equivalents/extract g. .

The total flavonoid content was measured according to the colorimetric method of aluminum chloride (Komkotbyul Kim et al. 2015). The extracted sample was diluted 10 times with methanol to make 10mg/ml, and 125μl of distilled water was added to 25μl of the sample, 7.5μl of 5% NaNO ₂ was added, mixed, and left for 6 minutes. Then, 15 μl of 10% AlCl3 was added, mixed again, and left for 5 minutes. Then, 50ul of 1M NaOH was added, and the absorbance was measured at 510nm. A calibration curve was drawn using catechin as a standard, and the total flavonoid content was expressed as mg catechin/extract g.

As a result of measuring the total phenol and total flavonoid content of the Udo peanut sprout extract, as shown in Table 1 below, the total polyphenol content was 10.87 mg gallic acid / g extract, and the total flavonoid content of Udo peanut sprout extract (PS) was 3.79. It was mg Catechin/g extract.

Peanut Sprout extract Total polyphenols (mg Gallic acid/extract g) 10.87±0.11 Total flavonoids (mg Catechin/extract g) 3.79±0.14 Resveratrol (μg/g) 18±0.01

<Experimental Example 2> Resveratrol content analysis

The sample was subjected to pretreatment by centrifuging the supernatant at 3000rpm for 30min and pulverizing the sample using a 0.45μm Teflon filter using a mortar, and the content of resveratrol was analyzed using High Performance Liquid Chromarograph (Shimadzu LC). The content of resveratrol was obtained by requesting the Institute for Polymer Chemistry, and detailed analysis conditions are as follows.

(1) Device name: Shimadzu LC

(2) HPLC column: Poroshell 120 EC-C18 (3.0*50mm)

(3) Column temperature: 40 ℃

(4) Solvent development conditions:

A: 0.1% Formic acid in D.W

B: 0.1% Formic acid in Acetonitrile

(5) Flow rate: 0.30 ml/min (6) Injection volume: 5 μL

Time(min) (A)% (B)% 0 60 40 5 30 70 8 5 95 10 5 95 10.01 60 40 15.0 60 40

(1) Device name: API 3200 (MS, Tandem Mass Spectrometry)

(2) Ion mode: ESI

(3) Polarity: Positive

(4) CUR: 10 ℃

(5) GS1: 40 ℃

(6) GS2: 40 ℃

(6) Source temp: 500 ℃

(7) Data processing: Analyst 1.6.2

(8) ion information

Ingredient name Q1 ¹⁾ Mass(Da) Q3 ²⁾ Mass(Da) Resveratrol 229.097 107.1

Note) 1) Q1: precursor ion, 2) Q3: product ion

The resveratol content of the peanut sprout extract was 1.8 ug / g (see Table 1). In addition, it could be seen that the peak of the Udo peanut sprout extract showed a resveratrol-specific peak compared to the peanut sprout extract of other regions (see FIGS. 1 and 2, Tables 4 and 5).

<Experimental Example 3> Measurement of cytotoxicity

The effect of the peanut sprout extract on the 3T3-L1 and C3H10T1/2 cell viability was confirmed according to the protocol using the XTT cell viability test kit (Cell Signaling Technology). Undifferentiated 3T3-L1 and C3H10T1/2 cells were cultured in 96-well plates at a density of ~ 20,000 cells/well.

Cells were incubated with DMSO or increasing concentrations of Udo Peanut sprout extract for 24 hours. After replacing the medium with a new medium containing the XTT solution at 37°C for 3 hours, OD 450 nm was measured using a microplate reader.

As a result of measuring the cytotoxicity, it was confirmed that the Udo peanut sprout extract did not show cytotoxicity as shown in FIG. 3.

<Experimental Example 4> Confirmation of lipid production inhibitory ability using Oil red O staining

To measure lipid accumulation in adipocytes, cells were fixed with 10% formalin and stained with Oil red O (ORO). Bright field images were taken with a CKX41 Inverted Microscope (Olympus), and the ORO dye was extracted with isopropanol to measure the relative TG (triglyceride) accumulation (OD 500 nm).

Udo peanut sprout extract was added to 3T3-L1 cells during differentiation and maintained for 10 days to confirm whether the Udo peanut sprout extract could inhibit adipogenesis. Udo peanut sprout extract (PS) (50, 100, 200 μg/ml) measured by ORO staining significantly reduced the accumulation of triglyceride (TG) (see FIG. 4).

In addition, the inhibitory effect of Udo peanut sprout extract on adipogenesis was confirmed in C3H10T1/2 mouse embryonic fibroblast and mouse primary adipocyte models. Udo peanut sprout extract (PS) (50 and 100 μg m) was measured by ORO staining, and as a result, triglyceride (TG) accumulation was remarkably reduced (see FIG. 7).

<Experimental Example 5> Total RNA extraction and qPCR analysis

Gene-specific primers for qPCR were prepared from Cosmo Genetech (Korea). Total RNA was isolated with Trizol reagent (Invitrogen), and mRNA was treated with DNase (Mediatech) to remove potential DNA contamination. RNA concentration was measured by NanoDrop (Nano-200 Micro-Spectrophotometer, Hangzhou City, China). A total of 1 μg of mRNA was converted into a total of 20 μl of cDNA (High-capacity cDNA reverse transcription kit, Applied Biosystem, USA). Gene expression real-time qPCR was confirmed by (CFX96™ real-time PCR detection system, Bio-Rad, USA).

As a result of confirming whether the Udo peanut sprout extract has an adipogenesis inhibitory effect at low concentration, PPARγ (Peroxisome proliferator-activated receptor gamma), FABP4 (fatty acid binding protein 4, aP2), C/EBPα (CCAAT/enhancer binding protein α) and Fas The expression of the adipogenic gene was significantly suppressed, including (fatty acid synthase) (see FIG. 5). Based on these results, 25 μg/ml Udo peanut sprout extract, which is the lowest dose that does not cause cell damage and has an anti-adipogenic effect, was used in the remaining experiments.

In addition, primary adipocytes extracted from EMSC were prepared. Bright-field pictures show differentiated primary adipocytes, and Udo peanut sprout extract (25μg/ml) significantly inhibited the formation of lipid droplets. In the same way as the TG accumulation inhibitory effect, the adipogenic gene PPARγ tended to be decreased by the Udo peanut sprout extract, and aP2 expression was significantly suppressed by the Udo peanut sprout extract (PS) (see FIG. 8).

<Experimental Example 6> Protein expression analysis using Western blot method

3T3-L1 adipocytes were scraped with RIPA Buffer (Thermo Scientific) containing a protease inhibitor (Sigma). Proteins were fractionated using 8 or 10% SDS-PAGE, transferred to a PVDF membrane, and related antibodies were incubated. ChemiDoc (Bio-Rad, CA, USA) was used to detect chemiluminescence from Western Lightning (ECL) solution. Polyclonal, monoclonal antibodies targeting phospho-AMPK (Thr172, # 2535), total AMPK (# 5831), PPARg (# 2435) and β-actin (# 4967) were purchased from Cell Signaling Technology, and aP2 (sc- 271529) was purchased from Santa Cruz Biotechnology.

In the expression of adipogenic proteins including aP2 and PPARγ, as a result of treatment with 25 μg/ml of Udo peanut sprout extract, protein expression was decreased (see FIG. 5). In addition, several phytochemicals are known to inhibit adipogenesis through mechanisms involved in AMP kinase (AMPK) activation. AMPK is known as an important energy detector that causes various catabolic processes and simultaneously inhibits anabolic pathways, and it was confirmed that the Udo peanut sprout extract treatment increased AMPK phosphorylation (see FIG. 6).

<Experimental Example 7> Fatty acid oxidation measurement

Udo peanut sprout extract (25μg/ml) for 4 days after making 3T3-L1 adipocytes into fully differentiated adipocytes according to the experimental design (see Fig. 9A) to check whether the Udo peanut sprout extract antagonizes adipocyte hypertrophy. Was treated.

Udo peanut sprout extract (25 μg/ml) treatment resulted in upregulation of fatty acid oxidation-related gene expression (PGC1a, CPT1, PPARγ) (significant reduction in lipogenic transcriptional activation measured by mRNA expression) (see FIG. 9B).

In addition, the fatty acid oxidation rate was measured using radio-labeled precursors to confirm whether the lipid-lowering effect of the Udo peanut sprout extract is involved in the lipogenic pathway. Fatty acid oxidation was confirmed due to the release of [3H] -H ₂ O from [3H] -OA, and treatment with the fatty acid [3H] -OA significantly increased fatty acid oxidation, confirming the accuracy of this method. As a result, it was confirmed that Udo peanut sprout extract (25 μg/ml) significantly increased fatty acid oxidation (see FIG. 9C).

After that, in order to find out whether the fat reduction effect of Udo peanut sprout extract is also involved in beige adipocyte formation characteristics, differentiated 3T3-L1 adipocytes were treated with Udo peanut sprout extract (25μg/ml) and beige adipocytes were mimicked. It was treated with Bt2cAMP, which is a cAMP analog for the following. Culture of mature adipocytes and Bt2cAMP was associated with the induction of UCP1 gene expression, and the induction was further enhanced by Udo peanut sprout extract (see Fig. 10).

<Experimental Example 8> Mitochondrial Respiration Activity Analysis

To investigate whether upregulation of fatty acid oxidation and changes in white adipocyte mitochondrial respiration function of Udo peanut extract are involved in the increase of beige adipocyte formation, oxygen consumption rate (OCR) was confirmed with the Seahorse system. In order to measure mitochondrial respiration activity, oxygen concentration of 3T3-L1 adipocytes was measured using an XF24 extracellular flow rate analyzer (Seahorse). After seeding 3T3-L1 cells in a coated microplate (24-well), adipogenic differentiation was induced as described above. Mitochondrial basal respiration was evaluated in cells without drug treatment, and cells were treated with oligomycin (oligo, 2 μM) to measure the ATP respiration rate. The maximum respiratory capacity was evaluated by the addition of carbonyl cyanide 4-trifluoromethoxy phenylhydrazone (FCCP, 0.5 μM), a chemical binding inhibitor of electron transport and oxidative phosphorylation. Mitochondrial respiration was blocked by a combination of antimycin A (1 μM) and rotenone (1 μM). Oxygen consumption rate (OCR) was calculated by calculating the O ₂ tension (pmol O ₂ /min) of the medium in the microenvironment above the cells as a function of time, and was analyzed as a value divided by the protein concentration.

As a result, Udo peanut sprout extract significantly increased OCR AUC and mitochondrial maximal respiration compared to the OCR peanut sprout untreated group (see FIG. 11).

So far, the present invention has been looked at around its preferred embodiments. Those of ordinary skill in the art to which the present invention pertains will be able to understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative point of view rather than a limiting point of view. The scope of the present invention is not shown in the foregoing description, but in the claims, and all differences within the scope should be construed as being included in the present invention.

Claims (9)

A pharmaceutical composition for the prevention or treatment of obesity, comprising a hot water extract of peanut sprout from Udosan. delete delete delete delete Health food composition for the prevention or improvement of obesity comprising a hot water extract of peanut sprout from Udo. The method of claim 6,
The health food is characterized in that the health food is selected from various drinks, meat, sausages, bread, candies, snacks, noodles, ice cream, dairy products, soups, ion drinks, beverages, alcoholic beverages, gum, tea, and vitamin complexes. Health food composition.
Health functional food composition for the prevention or improvement of obesity, comprising a peanut sprout extract from Udo. The method of claim 8,
The health functional food composition, characterized in that the food in the form of a tablet, capsule, pill or liquid.

Images